Price Gouging CEO DiCrisci Raises Cancer Drug Cost 1400%

Modesto Morganelli
Dicembre 28, 2017

Prices for a cancer drug called lomustine have skyrocketed almost 1,400 percent since 2013, putting a potentially life-saving treatment out of reach for patients suffering from brain tumors and Hodgkin's lymphoma.

Reports state that the 40-year-old life-saving cancer drug is not protected by patents any longer, and no generic version of the medication is now available in the market.

The remedy for brain tumors and Hodgkin lymphoma was introduced 42 years ago, and the highest dose was sold for $50 per capsule. The drugmaker sold lomustine in 2013 to a little-known Miami startup called NextSource, which proceeded to hike lomustine's price nine times since.

According to an analysis done for the Journal by Truveen Health Analytics and Elsevier, NextSource this year raised prices for the drug, which it rebranded as Gleostine, by 12 percent in November following a 20 percent increase in August. The medication now costs about $768 per pill.

NextSource CEO Robert DiCrisci, told the Wall Street Journal that the company "sets its prices based on the costs it incurred in developing the medication and the benefits it provides patients..."

Bottom line: DiCrisci is a despicable troll, buying up drug companies in order to exploit and profit from the pain and suffering of sick and vulnerable people by raising the prices of life saving medication.

A professor of neurosurgery at Duke University School of Medicine, Henry S. Friedman, said that either many people will suffer unfortunate events because they can not afford the medicines or many of them will face severe financial liability in an attempt to procure the drug. "People are not going to be able to afford it, or they're going to pay a lot of money and have financial liability". Lomustine has been around since 1976, and the patent has since expired, but it is one of more than 300 such drugs for which no generic version exists, notes the Journal.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE